FDA 483 - FairyGene Inc - January 15, 2026

FairyGene, Inc. in Bristol, PA, was inspected and received a Form 483 with five observations. The inspection revealed significant deficiencies in production and process controls, equipment cleaning, stability testing, facility design, and quality control unit procedures. These issues indicate a lack of adequate controls to ensure the quality and purity of their OTC drug products.